CLoNeT™: Fast, DNA-Based Antibiotic Stewardship

Our proprietary technology, CLoNeT™, is a revolutionary antibiotic stewardship tool. CLoNeT™ is a rapid (<45 min) diagnostic test that assigns proprietary ‘barcodes’ to infecting bacteria by identifying a few fingerprint regions of bacterial DNA. Our barcoding approach has broad applicability to diverse pathogens. CLoNeT™ holds the potential to improve clinical outcomes for multiple infectious diseases that are plagued with increasing antibiotic resistance.

First-generation CLoNeT™ tests target urinary tract infections, which are at the forefront of the drug resistance crisis. A partnership with GroupHealth Research Institute in Seattle, WA has permitted early stage clinical observational trials of first-generation CLoNeT™ in the urgent care setting.
In these urgent-care trials, our first-generation product delivered results in 25–40 minutes and cut the rate of antibiotic prescription errors for UTIs from 1 in 4 to under 3%.

Our projections indicate that CLoNeT™ 2.0 will bring error rates well below 3%. IDG’s R&D work has shown that the proprietary ‘barcoding’ method can also be applied to other infectious pathogens.

The next-generation product, CLoNeT™2.0, is currently under development. CLoNeT™R&D pipelines are also active for other infectious indications.
Amid widespread antibiotic resistance, our products encourage the use of appropriate antibiotics, ease the selective pressure that drives microbes to develop resistance, and help contain the spread of resistant organisms.

CLoNeT™ pairs fast DNA barcoding with a focus on antibiotic stewardship, so clinicians can choose the right antibiotic sooner. The same barcoding approach that powers the UTI tests is being explored for other infectious pathogens, with CLoNeT™ 2.0 in development.